null

null

null

null

null

null

null

null

null

0.18x Total Debt / Equity (Conservative)

Low direct sensitivity; Enveric carries minimal debt and is equity-financed through dilutive offerings, so rate shifts affect cost of capital for future raises, not existing leverage.

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

Synthetic psilocybin/psychedelic compound manufacturing concentrated in limited CMO facilities; API sourcing dependent on specialized North American and European chemical suppliers.

Negligible international revenue; USD-denominated operations only, so sovereign currency devaluation risk is effectively zero across all markets currently.

Effectively 100% U.S.-based preclinical/clinical operations; no material international revenue exposure to currency devaluation risk.

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

Single-source CMO dependency for proprietary psychedelic prodrug synthesis likely exceeds 30% of operational input cost; highly non-substitutable at current development stage.

Cloud disruption would be moderate; CRO data, regulatory filings, and research collaboration tools could migrate within 60–90 days with significant but not fatal operational disruption.

Pre-revenue clinical-stage biotech; no secondary cloud-dependent revenue stream exists—primary risk is data integrity for clinical trial management systems.

Low API coupling risk; company uses standard CRO platforms and regulatory software with no proprietary API integrations creating meaningful lock-in.

Minimal Howey risk; equity shares in a clinical-stage biotech satisfy standard securities framework; no token, royalty stream, or profit-sharing structure that complicates classification.

Very High

Moderate GDPR exposure via EU-based clinical trial participants; CCPA exposure minimal given no consumer-facing product. Clinical data governance is primary compliance burden.

Negligible antitrust exposure; pre-revenue niche psychedelic therapeutics company with no market dominance, no pricing power, and no horizontal consolidation activity.

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

0% recurring revenue currently; 100% transactional/grant/collaboration-based. Company is pre-commercialization with no approved product generating revenue.

Future monetization expected via licensing IP or milestone/royalty payments from pharma partners; no current product sales or subscription revenue.

No commercial pricing architecture exists; future pricing will be driven by payer reimbursement dynamics for psychedelic-assisted therapy, historically difficult to model pre-approval.

Undetermined pre-approval; if approved, orphan-like pricing potential for novel mechanism CNS drugs, but payer resistance to high-cost psychiatric drugs limits ceiling.

20.4% Gross Margin (Moderate (20-40%))

No free-rider risk applicable; pre-revenue biotech with no commercial product. Research collaboration partners are contractually bound with milestones.

Headcount-linear at current stage; scaling clinical trials requires proportional CRO and scientific staff additions. Fixed G&A provides modest sublinear benefit at scale.

Marginal cost of growth is high and capital-intensive; each pipeline program requires $10M–$50M+ in clinical spend before generating any revenue.

Not applicable; Enveric operates no franchise network.

At 10x scale, CAC economics remain undefined pre-commercialization; pharma licensing model implies low volume/high value deals with long sales cycles and high BD costs.

No network effects present; proprietary drug development IP does not benefit from user scale or data network dynamics.

-172.1% Return on Assets (Negative equity)

Low recession resistance; dependent on equity capital markets for survival. In recessions, biotech financing dries up, directly threatening operations for a cash-burning pre-revenue company.

Primary future customers are large pharma/biotech licensees and payers; currently dependent on a handful of research grant bodies and collaboration partners—high concentration risk.

Secondary segment includes academic medical centers and CROs as trial execution partners; not revenue-generating customers but operationally critical with moderate concentration.

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

0.0% CapEx / Revenue (Low-CapEx Asset-Light)

0000890821

ENVB